课题基金 / 基金详情

Targeting bone morphogenetic protein-9 as an angioproliferative switch in pulmonary arterial hypertension

Targeting bone morphogenetic protein-9 as an angioproliferative switch in pulmonary arterial hypertension
靶向骨形态发生蛋白 9 作为肺动脉高压的血管增殖开关
批准号：
443722
负责人：
Ormiston Mark L
金额：
$57.4万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2026-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443722&lang=en
关键词：
Angiogenesis Bone Morphogenetic Proteins Conditional Knockout Mouse Models Endothelial Cells Pulmonary Arterial Hypertension Transcriptomics Type Ii Bone Morphogenetic Protein Receptor (Bmpr2)

项目摘要

项目成果

Ormiston Mark L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pulmonary arterial hypertension (PAH) is a fatal disease that preferentially targets young women in their 30s and 40s. PAH involves the disordered and uncontrolled growth of blood vessels in the lung. This overgrowth leads to obstruction of these vessels,
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Examining the role for natural killer cell TGFb signaling in pulmonary vascular development and the pathogenesis of pulmonary hypertension
Canada Research Chairs - Tier 2
Cellular and molecular mechanisms of Natural Killer cell-mediated vascular remodeling in pulmonary arterial hypertension
Cellular and molecular mechanisms of Natural Killer cell-mediated vascular remodeling in pulmonary arterial hypertension
国内基金
海外基金
骨形态发生蛋白（Bone Morphogenetic Proteins,BMP）信号在脊髓损伤中枢神经性疼痛中的作用
  • 批准号：
    81070994
  • 项目类别：
    面上项目
  • 资助金额：
    32.0万元
  • 批准年份：
    2010
  • 负责人：
    王亚平
  • 依托单位：
    中南大学